Back

Net clinical benefit of 18-month over 6-month rivaroxaban in patients with cancer and acute low-risk pulmonary embolism: Insight from the ONCO PE trial

21 June 2025 (10:23 - 10:32)
Organised by: Logo
Congress Presentation Part of: Management of cardiovascular disease in cancer patients and survivors Diagnosis and Management of Cardiovascular Disease in Patients with Cancer CCO Premium Access ESC Cardio-Oncology 2025 Council of Cardio-Oncology

About the speaker

Photo
Doctor Yuji Nishimoto

Toyonaka Municipal Hospital, Toyonaka (Japan)

4 More presentations in this session

Presentation thumbnail
Arterial stiffness in cancer survivors: the prognostic value of estimated pulse wave velocity (ePWV) in U.S cancer population from NHANES 2009-2018
Doctor M. Al-Jarshawi (Stoke-on-Trent, GB)
Abstract Slides Video
Presentation thumbnail
Disparities between cardiologists and oncologists therapeutic strategies in cardio-oncology. A national cross-sectional survey
Assistant Professor A. Ivanescu (Bucharest, RO)
Abstract Slides Video
Presentation thumbnail
Clinical outcomes of half-dose extended anticoagulation in cancer-associated pulmonary thromboembolism: a real-world cohort study
Doctor M. Bak (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Endothelial syndrome as a life-threatening complication in haematopoietic stem cell transplantation
Doctor V. Cetoretta (Ancona, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Management of cardiovascular disease in cancer patients and survivors

The Event

Event poster

ESC Cardio-Oncology 2025

21 June 2025 10:23 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of prolonged rivaroxaban treatment for high-bleeding risk cancer patients with acute low-risk pulmonary embolism: a post-hoc subgroup analysis of the ONCO PE trial
thumbnail
Congress Presentation
Clinical outcomes of half-dose extended anticoagulation in cancer-associated pulmonary thromboembolism: a real-world cohort study
thumbnail
Congress Presentation
ONCO DVT Study; Optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis in patients with cancer study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources